WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events:
- Wells Fargo 21st Annual Healthcare Conference in Boston, MA on September 9 at 8:00 AM ET;
- Citi 2026 Biopharma Back to School Summit in New York, NY on September 10 at 11:20 AM ET;
- H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on September 14 at 4:30 PM ET;
- Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY on September 15 at 7:45 AM ET; and
- Stifel 2026 Virtual Immunology and Inflammation Forum on September 24 at 11:00 AM ET.
Live webcasts of the events will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor Contact:
Justine Koenigsberg
[email protected]
857-285-5300
Media Contact:
Matthew Henson
[email protected]
857-285-5300